Search research articles
Contact Us
Filters
Showing results (51-60 of 115) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
April 25, 2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study
Julie M Vose, Siddhartha Ganguly, Philip J Bierman, et al.
Experimental Biology and Medicine (Maywood, N.J.)
|
August 9, 2020
Analysis of epigenetic aging <i>in vivo</i> and <i>in vitro</i>: Factors controlling the speed and direction
Mieko Matsuyama, Arne Søraas, Sarah Yu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 29, 2021
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates
Madison Keenan, Akiva Diamond, Kirsten Boughan, et al.
Future Oncology (London, England)
|
November 7, 2024
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
Cancer Discovery
|
May 13, 2022
Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Zachary Jackson, Changjin Hong, Robert Schauner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2020
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"
A M Evens, K R Carson, J Kolesar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
A M Evens, K R Carson, J Kolesar, et al.
Ejhaem
|
February 26, 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
Oncotarget
|
November 8, 2017
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies
Paolo F Caimi, Brenda W Cooper, Basem M William, et al.
Frontiers in Oncology
|
March 27, 2020
Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
Masumi Ueda, Tammy Stefan, Lindsay Stetson, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 115) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
April 25, 2023
Lenalidomide maintenance following high-dose therapy and autologous haematopoietic stem cell transplantation in chemo-resistant or high-risk non-Hodgkin lymphoma: A phase I/II study
Julie M Vose, Siddhartha Ganguly, Philip J Bierman, et al.
Experimental Biology and Medicine (Maywood, N.J.)
|
August 9, 2020
Analysis of epigenetic aging <i>in vivo</i> and <i>in vitro</i>: Factors controlling the speed and direction
Mieko Matsuyama, Arne Søraas, Sarah Yu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 29, 2021
Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates
Madison Keenan, Akiva Diamond, Kirsten Boughan, et al.
Future Oncology (London, England)
|
November 7, 2024
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
Cancer Discovery
|
May 13, 2022
Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Zachary Jackson, Changjin Hong, Robert Schauner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2020
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"
A M Evens, K R Carson, J Kolesar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
A M Evens, K R Carson, J Kolesar, et al.
Ejhaem
|
February 26, 2024
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, et al.
Oncotarget
|
November 8, 2017
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies
Paolo F Caimi, Brenda W Cooper, Basem M William, et al.
Frontiers in Oncology
|
March 27, 2020
Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
Masumi Ueda, Tammy Stefan, Lindsay Stetson, et al.
Page
of 12